Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.72 |
| ▸ | HTR2A | P28223 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.54 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.54 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8088821 | 1.00 | HTR2C (0.72) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL8333213 | 0.88 | HTR2C (0.68) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL23995531 | 0.85 | HTR2C (0.74) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL20205056 | 0.85 | HTR2C (0.74) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL22334915 | 0.85 | HTR2C (0.74) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL15255094 | 0.84 | HTR2C (1.00) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL8097675 | 0.84 | HTR2C (1.00) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL8097678 | 0.84 | HTR2C (1.00) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL8332428 | 0.84 | HTR2C (0.72) | HTR2CHTR2AHTR2BCHRM2CHRM1 | |
| SCHEMBL6319621 | 0.82 | HTR2A (0.65) | HTR2CHTR2AHTR2BCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102198-B1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10059667-B2 | Antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-3102198-A1 | ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-11-17 | — | — | US | disclosed |
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-11-17 | — | — | US | disclosed |
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-11-17 | — | — | US | disclosed |
| WO-2015119899-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-08-13 | — | — | WO | disclosed |
| WO-2015119899-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-08-13 | — | — | WO | disclosed |
| EP-0747346-B1 | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL MYERS SQUIBB CO (US) | 2000-02-16 | — | — | EP | disclosed |
| US-5889031-A | CONTROLLING CIRCADIAN RHYTHMS | BRISTOL-MYERS SQUIBB COMPNAY (US) | 1999-03-30 | — | — | US | disclosed |
| US-5753709-A | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0747346-A2 | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | GPR119, GLP1R, GIPR | HTR2C 986/4885HTR2A 485/4885HTR2B 901/4885 |
| US-10059667-B2 | Antidiabetic compounds | GPR119, GLP1R, GIPR | HTR2C 986/4885HTR2A 485/4885HTR2B 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.